Close this search box.

DC4 supervisor

Dr. Sarah Cianferani

Centre National de la Recherche Scientifique (CNRS), Institut Pluridisciplinaire Hubert Curien –  IPHC UMR, France

Dr. Sarah CIANFERANI is a research Director at the National Center for Scientific Research (CNRS) in France. She is currently heading the BioOrganic Mass Spectrometry Laboratory at the Institut Pluridisciplinaire Hubert Curien (IPHC) in Strasbourg, a team of 45 people that has strong expertise in proteomic analyses and structural mass spectrometry.

Her expertise focuses on developments in structural mass spectrometry and applications of advanced native mass spectrometry and native ion-mobility mass spectrometry methodologies for biological noncovalent complex characterization, and especially biopharmaceuticals.

Dr. Sarah Cianférani holds a PhD degree in analytical chemistry from the University of Strasbourg, France. She performed and post-doctoral fellowship at the Institute for Genetics and Molecular Biology (IGBMC) in Strasbourg to gain expertise in structural biology. She then joined the AliX company to develop native Mass Spectrometry for protein/ligand screening. She was recruited by the CNRS as researcher in 2004 in the team of Alain Van Dorsselaer (BioOrganic Mass Spectrometry Lab, LSMBO) in Strasbourg. She is now research director at the CNRS and heads the BioOrganic Mass Spectrometry Laboratory (LSMBO). Her group is part of the French National Proteomic Infrastructure ProFI). She is co-author of more than 260 scientific papers related to mass spectrometry analysis of proteins.

“MobiliTraIN will boost ion mobility MS (IM-MS) instrumental and methodological developments, foster standardisation of datasets in order to be applied in different industrial sectors including for biopharma companies to deliver better and safer biotherapeutics. MobiliTraIN is a unique way to be training on an exciting technology, within an interdisciplinary consortium. Make your own opinion and join us!”

Selected Publications

  1. Online Collision-Induced Unfolding of Therapeutic Monoclonal Antibody Glyco-Variants through Direct Hyphenation of Cation Exchange Chromatography with Native Ion Mobility-Mass Spectrometry.  van Schaick G, Domínguez-Vega E, Castel J, Wuhrer M, Hernandez-Alba O, Cianférani S. Anal Chem. 2023 Feb 28;95(8):3932-3939. doi: 10.1021/acs.analchem.2c03163.
  2. Benefits and Limitations of High-Resolution Cyclic IM-MS for Conformational Characterization of Native Therapeutic Monoclonal Antibodies.  Deslignière E, Ollivier S, Beck A, Ropartz D, Rogniaux H, Cianférani S. Anal Chem. 2023 Feb 28;95(8):4162-4171. doi: 10.1021/acs.analchem.2c05265.
  3. Combination of IM-Based Approaches to Unravel the Coexistence of Two Conformers on a Therapeutic Multispecific mAb.  Deslignière E, Ollivier S, Ehkirch A, Martelet A, Ropartz D, Lechat N, Hernandez-Alba O, Menet JM, Clavier S, Rogniaux H, Genet B, Cianférani S. Anal Chem. 2022 Jun 7;94(22):7981-7989. doi: 10.1021/acs.analchem.2c00928.
  4. Middle Level IM-MS and CIU Experiments for Improved Therapeutic Immunoglobulin Subclass Fingerprinting. Botzanowski T, Hernandez-Alba O, Malissard M, Wagner-Rousset E, Deslignière E, Colas O, Haeuw JF, Beck A, Cianférani S. Anal Chem. 2020 Jul 7;92(13):8827-8835. doi: 10.1021/acs.analchem.0c00293.
  5. Toward Automation of Collision-Induced Unfolding Experiments through Online Size Exclusion Chromatography Coupled to Native Mass Spectrometry. Deslignière E, Ehkirch A, Botzanowski T, Beck A, Hernandez-Alba O, Cianférani S. Anal Chem. 2020 Oct 6;92(19):12900-12908. doi: 10.1021/acs.analchem.0c01426.